PULSE BIOSCIENCES, INC. 8-K

What Happened

• Pulse Biosciences, Inc. (PLSE) held its 2026 Annual Meeting of Stockholders on June 11, 2026 as a virtual live audio webcast and filed an 8-K reporting the results. Seven director nominees were elected to serve until the 2027 annual meeting, and stockholders ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Director election results (For / Against / Abstained / Broker non-votes = 10,974,550):
  • Robert W. Duggan: 33,443,582 / 1,583,174 / 388
  • Paul A. LaViolette: 34,264,295 / 759,401 / 3,448
  • Maria Sainz: 35,007,101 / 18,349 / 1,694
  • Manmeet S. Soni: 33,560,875 / 1,464,574 / 1,695
  • Darrin R. Uecker: 34,246,413 / 779,036 / 1,695
  • Richard A. van den Broek: 34,278,978 / 746,471 / 1,695
  • Mahkam Zanganeh, D.D.S.: 34,241,938 / 783,511 / 1,695
• Auditor ratification vote: For 45,976,355; Against 8,265; Abstained 17,074 (broker non-votes: N/A). The appointment of Deloitte & Touche LLP was ratified for fiscal year ending December 31, 2026.
• Each elected director will serve until the 2027 annual meeting and until a successor is duly elected and qualified.

Why It Matters

• The election results confirm the board’s composition for the coming year, which determines who oversees corporate strategy and governance.
• Ratification of Deloitte & Touche LLP secures the company’s independent auditor for fiscal 2026, providing continuity for financial reporting and the annual audit.